The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board and resolved to pay a dividend of EUR 0.22 per share (previous year: EUR 0.17) for the 2025 fiscal year. As in previous years, the Annual General Meeting was held as an in-person event, right next to the Eckert & Ziegler SE headquarters in Berlin. In total, 55.37 % of the company’s share capital was represented. The Annual General Meeting endorsed the members of the Executive Board and the Supervisory Board of Eckert & Ziegler SE for the 2025 fiscal year and approved all items on the agenda by a large majority.
The dividend increase of nearly 30% signals confidence in the company's financial health and future prospects. Eckert & Ziegler SE, a leading specialist for isotope-related components in nuclear medicine and radiation therapy, continues to demonstrate strong performance. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. With more than 1,000 employees, Eckert & Ziegler shares are listed in the TecDAX index of Deutsche Börse.
The detailed voting results of the Annual General Meeting and the CEO’s presentation are available on the Eckert & Ziegler SE website: https://www.ezag.com/investors/annual-general-meeting/. This announcement underscores the company's commitment to returning value to shareholders while maintaining its focus on saving lives through innovative medical solutions.
